(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said on Thursday.

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial, the drugmaker said Monday.

As part of the collaboration, the drugmaker will use Immunai's AI model of the immune system and machine learning for clinical decision-making in drug discovery and development The post Israeli AI startup forges $18m partnership with AstraZeneca for cancer drug trials appeared first on The Times of Israel.

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.

Under the terms of the agreement, AstraZeneca will leverage Immunai’s platform and machine learning capabilities to inform certain oncology clinical trials.